195 results
8-K
EX-99.1
LSTA
Lisata Therapeutics Inc
16 Sep 04
Unregistered Sales of Equity Securities
12:00am
, Financial Development and Business Analysis
Phase III Medical (OTCBB:PHSM), an innovative business that
provides capital and guidance to companies … to working
closely with them to develop this innovative enterprise."
About Phase III Medical
Phase III Medical (OTCBB:PHSM), a Delaware
8-K
EX-99.2
LSTA
Lisata Therapeutics Inc
20 Nov 06
Departure of Directors or Principal Officers
12:00am
NEOSTEM, INC. APPOINTS INNOVATIVE LEADER IN COMPETITIVE BUSINESS
PROCUREMENT AND MANAGEMENT TO THE COMPANY'S BOARD OF DIRECTORS
NEW … in innovative enterprises. A serial
entrepreneur, Mr. Myers has spearheaded a number of business innovations in
aerospace & defense and in business
8-K
EX-99.1
LSTA
Lisata Therapeutics Inc
23 Feb 09
Other Events
12:00am
Exhibit 99.1
NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation … signed a license agreement to obtain the exclusive worldwide rights to innovative stem cell technology and applications for cosmetic facial and body
8-K
LSTA
Lisata Therapeutics Inc
1 Feb 10
Regulation FD Disclosure
12:00am
including antibiotics. These business units are expected to provide platforms for the accelerated development and commercialization of innovative … development and commercialization of innovative technologies and products in both the U.S. and China.
Adult Stem Cell Business in the U.S.
Stem cells
8-K
EX-99.1
LSTA
Lisata Therapeutics Inc
11 Jul 23
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
4:01pm
” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases … Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative
8-K
EX-99.2
zcfj put6usfvb1rk
14 Mar 19
Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results
4:18pm
8-K
EX-99.1
eq1jgy3j
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
8-K
EX-99.1
p6sre6z4w8w2
9 May 24
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:08pm
425
3mx05
9 Jun 22
Business combination disclosure
4:01pm
8-K
EX-99.1
2t5a9c9fz5ye0zhvl
15 Sep 22
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
9:16am
8-K
EX-99.2
uqnb7
4 Nov 21
Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results
4:09pm
8-K
EX-99.2
quiajy alvg9g
22 Mar 22
Caladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
4:09pm
DEFA14A
306emrxd zfnhj
16 Apr 09
Additional proxy soliciting materials
12:00am
8-K
EX-99.1
faay4di mm38
14 Mar 19
Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results
4:18pm
8-K
EX-99.1
0q1h evuo9yps91v
23 May 22
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction
4:08pm
8-K
EX-99.1
zjygmts39lk5o2c
16 Mar 07
Regulation FD Disclosure
12:00am
8-K
EX-99.1
b94 5qralbjvd9aopq9u
4 Nov 21
Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results
4:09pm
8-K
EX-99.1
33s vuvitytvupw
9 May 23
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.1
lxi 4k6mi3sxb1a
22 Mar 22
Caladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
4:09pm
425
hqoz214c ruo42pmhq
6 Jul 22
Business combination disclosure
4:05pm